<- Go Home
TELA Bio, Inc.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Market Cap
$39.6M
Volume
182.2K
Cash and Equivalents
$29.7M
EBITDA
-$34.4M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$52.2M
Profit Margin
67.73%
52 Week High
$3.20
52 Week Low
$0.86
Dividend
N/A
Price / Book Value
25.89
Price / Earnings
-1.12
Price / Tangible Book Value
391.42
Enterprise Value
$51.4M
Enterprise Value / EBITDA
-1.51
Operating Income
-$35.5M
Return on Equity
1654.21%
Return on Assets
-38.68
Cash and Short Term Investments
$29.7M
Debt
$41.5M
Equity
$1.6M
Revenue
$77.1M
Unlevered FCF
N/A
Sector
Health Care Equipment and Supplies
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium